Literature DB >> 22764233

Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1.

Xian Lin1, Loukia Parisiadou, Carmelo Sgobio, Guoxiang Liu, Jia Yu, Lixin Sun, Hoon Shim, Xing-Long Gu, Jing Luo, Cai-Xia Long, Jinhui Ding, Yolanda Mateo, Patricia H Sullivan, Ling-Gang Wu, David S Goldstein, David Lovinger, Huaibin Cai.   

Abstract

α-Synuclein (α-syn) plays a prominent role in the degeneration of midbrain dopaminergic (mDA) neurons in Parkinson's disease (PD). However, only a few studies on α-syn have been performed in the mDA neurons in vivo, which may be attributed to a lack of α-syn transgenic mice that develop PD-like severe degeneration of mDA neurons. To gain mechanistic insights into the α-syn-induced mDA neurodegeneration, we generated a new line of tetracycline-regulated inducible transgenic mice that overexpressed the PD-related α-syn A53T missense mutation in the mDA neurons. Here we show that the mutant mice developed profound motor disabilities and robust mDA neurodegeneration, resembling some key motor and pathological phenotypes of PD. We also systematically examined the subcellular abnormalities that appeared in the mDA neurons of mutant mice and observed a profound decrease of dopamine release, the fragmentation of Golgi apparatus, and the impairments of autophagy/lysosome degradation pathways in these neurons. To further understand the specific molecular events leading to the α-syn-dependent degeneration of mDA neurons, we found that overexpression of α-syn promoted a proteasome-dependent degradation of nuclear receptor-related 1 protein (Nurr1), whereas inhibition of Nurr1 degradation ameliorated the α-syn-induced loss of mDA neurons. Given that Nurr1 plays an essential role in maintaining the normal function and survival of mDA neurons, our studies suggest that the α-syn-mediated suppression of Nurr1 protein expression may contribute to the preferential vulnerability of mDA neurons in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764233      PMCID: PMC3417246          DOI: 10.1523/JNEUROSCI.1731-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

Review 1.  Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra.

Authors:  Marten P Smidt; Simone M Smits; J Peter H Burbach
Journal:  Cell Tissue Res       Date:  2004-08-06       Impact factor: 5.249

2.  Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.

Authors:  Y Matsuoka; M Vila; S Lincoln; A McCormack; M Picciano; J LaFrancois; X Yu; D Dickson; W J Langston; E McGowan; M Farrer; J Hardy; K Duff; S Przedborski; D A Di Monte
Journal:  Neurobiol Dis       Date:  2001-06       Impact factor: 5.996

3.  Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

Authors:  Masaki Wakamatsu; Aiko Ishii; Shingo Iwata; Junko Sakagami; Yuriko Ukai; Mieko Ono; Daiji Kanbe; Shin-ichi Muramatsu; Kazuto Kobayashi; Takeshi Iwatsubo; Makoto Yoshimoto
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

4.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

5.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

6.  Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.

Authors:  Suzana Gispert; Domenico Del Turco; Lisa Garrett; Amy Chen; David J Bernard; John Hamm-Clement; Horst-Werner Korf; Thomas Deller; Heiko Braak; Georg Auburger; Robert L Nussbaum
Journal:  Mol Cell Neurosci       Date:  2003-10       Impact factor: 4.314

7.  The G59S mutation in p150(glued) causes dysfunction of dynactin in mice.

Authors:  Chen Lai; Xian Lin; Jayanth Chandran; Hoon Shim; Wan-Jou Yang; Huaibin Cai
Journal:  J Neurosci       Date:  2007-12-19       Impact factor: 6.167

Review 8.  Transgenic rodent models of Parkinson's disease.

Authors:  B K Harvey; Y Wang; B J Hoffer
Journal:  Acta Neurochir Suppl       Date:  2008

9.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

10.  Toxin-induced and genetic animal models of Parkinson's disease.

Authors:  Shin Hisahara; Shun Shimohama
Journal:  Parkinsons Dis       Date:  2010-12-22
View more
  85 in total

1.  Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFAD mice, an animal model of Alzheimer's disease.

Authors:  Minho Moon; Inhye Jeong; Chun-Hyung Kim; Jihong Kim; Paula K J Lee; Inhee Mook-Jung; Pierre Leblanc; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2014-09-16       Impact factor: 5.372

Review 2.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 3.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

4.  Tau haploinsufficiency causes prenatal loss of dopaminergic neurons in the ventral tegmental area and reduction of transcription factor orthodenticle homeobox 2 expression.

Authors:  Meige Zheng; Luyan Jiao; Xiaolu Tang; Xianhong Xiang; Xiaomei Wan; Yan Yan; Xingjian Li; Guofeng Zhang; Yonglin Li; Bin Jiang; Huaibin Cai; Xian Lin
Journal:  FASEB J       Date:  2017-04-19       Impact factor: 5.191

5.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

6.  Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.

Authors:  Li Gan; Marcelo R Vargas; Delinda A Johnson; Jeffrey A Johnson
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

7.  Autophagy alleviates neurodegeneration caused by mild impairment of oxidative metabolism.

Authors:  Ya Meng; Yue Yong; Guang Yang; Hanqing Ding; Zhiqin Fan; Yifen Tang; Jia Luo; Zun-Ji Ke
Journal:  J Neurochem       Date:  2013-06-09       Impact factor: 5.372

8.  Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.

Authors:  Xiaobo Wei; Huimin Gao; Jing Zou; Xu Liu; Dan Chen; Jinchi Liao; Yunqi Xu; Long Ma; Beisha Tang; Zhuohua Zhang; Xiang Cai; Kunling Jin; Ying Xia; Qing Wang
Journal:  Mol Neurobiol       Date:  2015-10-26       Impact factor: 5.590

9.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.

Authors:  Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

10.  VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.

Authors:  Chen Wang; Mengxi Niu; Zehua Zhou; Xiaoyuan Zheng; Lingzhi Zhang; Ye Tian; Xiaojun Yu; Guojun Bu; Huaxi Xu; Qilin Ma; Yun-Wu Zhang
Journal:  Neurobiol Aging       Date:  2016-05-21       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.